Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis

James D. Berry; Jeremy M. Shefner; Robin Conwit; David Schoenfeld; Myles Keroack; Donna Felsenstein; Lisa Krivickas; William S. David; Francine Vriesendorp; Alan Pestronk; James B. Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jeffrey D. Rothstein; David J. Greenblatt; Merit E. Cudkowicz

doi:10.1371/journal.pone.0061177

Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis

James D. Berry, Jeremy M. Shefner, Robin Conwit, David Schoenfeld, Myles Keroack, Donna Felsenstein, Lisa Krivickas, William S. David, Francine Vriesendorp, Alan Pestronk, James B. Caress, Jonathan Katz, Ericka Simpson, Jeffrey Rosenfeld, Robert Pascuzzi, Jonathan Glass, Kourosh Rezania, Jeffrey D. Rothstein, David J. Greenblatt, Merit E. Cudkowicz

Neurology

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	e61177
Journal	PLoS ONE
Volume	8
Issue number	4
DOIs	https://doi.org/10.1371/journal.pone.0061177
State	Published - Apr 17 2013

ASJC Scopus Subject Areas

General

Access to Document

10.1371/journal.pone.0061177

OpenUrl availability

Full text

Cite this

Berry, J. D., Shefner, J. M., Conwit, R., Schoenfeld, D., Keroack, M., Felsenstein, D., Krivickas, L., David, W. S., Vriesendorp, F., Pestronk, A., Caress, J. B., Katz, J., Simpson, E., Rosenfeld, J., Pascuzzi, R., Glass, J., Rezania, K., Rothstein, J. D., Greenblatt, D. J., & Cudkowicz, M. E. (2013). Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis. PLoS ONE, 8(4), Article e61177. https://doi.org/10.1371/journal.pone.0061177

Berry, JD, Shefner, JM, Conwit, R, Schoenfeld, D, Keroack, M, Felsenstein, D, Krivickas, L, David, WS, Vriesendorp, F, Pestronk, A, Caress, JB, Katz, J, Simpson, E, Rosenfeld, J, Pascuzzi, R, Glass, J, Rezania, K, Rothstein, JD, Greenblatt, DJ & Cudkowicz, ME 2013, 'Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis', PLoS ONE, vol. 8, no. 4, e61177. https://doi.org/10.1371/journal.pone.0061177

@article{e571ab44079c4ce9aa02b99293e946e6,

title = "Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis",

author = "Berry, {James D.} and Shefner, {Jeremy M.} and Robin Conwit and David Schoenfeld and Myles Keroack and Donna Felsenstein and Lisa Krivickas and David, {William S.} and Francine Vriesendorp and Alan Pestronk and Caress, {James B.} and Jonathan Katz and Ericka Simpson and Jeffrey Rosenfeld and Robert Pascuzzi and Jonathan Glass and Kourosh Rezania and Rothstein, {Jeffrey D.} and Greenblatt, {David J.} and Cudkowicz, {Merit E.}",

note = "Funding Information: JDB has served as a consultant to Biogen Idec and as a paid speaker for Oakstone Publishing. He receives research report from the Muscular Dystrophy Association and ALS Therapy Alliance. JMS has served as a consultant to Biogen Idec, Cytokinetics, Trophos, ISIS, Glaxo Smith Kline, and receives research support from the Muscular Dystrophy Association, ALS Association, ALS Therapy Alliance, Cytokinetics, Biogen Idec, Sanofi Aventis, Neuraltus. RC is employed at the National Institute of Neurological Disorders and Stroke. DS, over the last 24 months, has served as a biostatistical consultant to Averion, Inc, Gerson Lehrman Group, Guidepoint Global, Neuronova, Cytokinetics, Glaxo Smith Kline, Merck, Aggennix, Pfizer, Biogen Idec, and Elan. He has received research support from AstraZeneca, Roche, CytRx, and ISIS. MK has no relevant disclosures to report. DF has received research funds from Euroimmune, Allere, Focus, Biokit, BioRad and Diasorin, Chronic Fatigue Initiative. LK has no relevant disclosures to report. WSD has no relevant disclosures to report. FV has no relevant disclosures to report. AP receives revenue related to antibody patent licenses from Athena; owns stock in Johnson & Johnson; directs the Washington University Neuromuscular Clinical Laboratory which performs antibody testing; and receives research support from the National Institutes of Health, Muscular Dystrophy Association, Neuromuscular Research Fund, Insmed, Knopp, Cytokinetics, Biogen Idec, ISIS, Genzyme, GSK, Ultragenyx & Sanofi. JBC has no relevant disclosures to report. JK has no relevant disclosures to report. ES has no relevant disclosures to report. JR has served on scientific advisory boards and/or as a consultant for Hill-ROM Inc, Cytokinetics and Avanir Pharmaceuticals. RP has no relevant disclosures to report. JG receives research support from the Muscular Dystrophy Association and from the National Institute of Neurological Disorders and Stroke. KR has no relevant disclosures to report. JR has research funding from National Institutes of Health, Department of Defense, P2ALS, Muscular Dystrophy Association, Robert Packard Center for ALS Research at Johns Hopkins. He has acted as a consultant to Biogen Idec, Cytokinetics and Psyadon Pharmaceuticals, Inc. DJG has no relevant disclosures to report. MEC served on DSMB for Synapse and Trophos and was a consultant for TEVA, Millenium, GlaxoSmithKline and Biogen. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. ",

year = "2013",

month = apr,

day = "17",

doi = "10.1371/journal.pone.0061177",

language = "English",

volume = "8",

journal = "PLoS ONE",

issn = "1932-6203",

number = "4",

}

TY - JOUR

T1 - Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis

AU - Berry, James D.

AU - Shefner, Jeremy M.

AU - Conwit, Robin

AU - Schoenfeld, David

AU - Keroack, Myles

AU - Felsenstein, Donna

AU - Krivickas, Lisa

AU - David, William S.

AU - Vriesendorp, Francine

AU - Pestronk, Alan

AU - Caress, James B.

AU - Katz, Jonathan

AU - Simpson, Ericka

AU - Rosenfeld, Jeffrey

AU - Pascuzzi, Robert

AU - Glass, Jonathan

AU - Rezania, Kourosh

AU - Rothstein, Jeffrey D.

AU - Greenblatt, David J.

AU - Cudkowicz, Merit E.

N1 - Funding Information: JDB has served as a consultant to Biogen Idec and as a paid speaker for Oakstone Publishing. He receives research report from the Muscular Dystrophy Association and ALS Therapy Alliance. JMS has served as a consultant to Biogen Idec, Cytokinetics, Trophos, ISIS, Glaxo Smith Kline, and receives research support from the Muscular Dystrophy Association, ALS Association, ALS Therapy Alliance, Cytokinetics, Biogen Idec, Sanofi Aventis, Neuraltus. RC is employed at the National Institute of Neurological Disorders and Stroke. DS, over the last 24 months, has served as a biostatistical consultant to Averion, Inc, Gerson Lehrman Group, Guidepoint Global, Neuronova, Cytokinetics, Glaxo Smith Kline, Merck, Aggennix, Pfizer, Biogen Idec, and Elan. He has received research support from AstraZeneca, Roche, CytRx, and ISIS. MK has no relevant disclosures to report. DF has received research funds from Euroimmune, Allere, Focus, Biokit, BioRad and Diasorin, Chronic Fatigue Initiative. LK has no relevant disclosures to report. WSD has no relevant disclosures to report. FV has no relevant disclosures to report. AP receives revenue related to antibody patent licenses from Athena; owns stock in Johnson & Johnson; directs the Washington University Neuromuscular Clinical Laboratory which performs antibody testing; and receives research support from the National Institutes of Health, Muscular Dystrophy Association, Neuromuscular Research Fund, Insmed, Knopp, Cytokinetics, Biogen Idec, ISIS, Genzyme, GSK, Ultragenyx & Sanofi. JBC has no relevant disclosures to report. JK has no relevant disclosures to report. ES has no relevant disclosures to report. JR has served on scientific advisory boards and/or as a consultant for Hill-ROM Inc, Cytokinetics and Avanir Pharmaceuticals. RP has no relevant disclosures to report. JG receives research support from the Muscular Dystrophy Association and from the National Institute of Neurological Disorders and Stroke. KR has no relevant disclosures to report. JR has research funding from National Institutes of Health, Department of Defense, P2ALS, Muscular Dystrophy Association, Robert Packard Center for ALS Research at Johns Hopkins. He has acted as a consultant to Biogen Idec, Cytokinetics and Psyadon Pharmaceuticals, Inc. DJG has no relevant disclosures to report. MEC served on DSMB for Synapse and Trophos and was a consultant for TEVA, Millenium, GlaxoSmithKline and Biogen. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

PY - 2013/4/17

Y1 - 2013/4/17

UR - http://www.scopus.com/inward/record.url?scp=84876243023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876243023&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0061177

DO - 10.1371/journal.pone.0061177

M3 - Article

C2 - 23613806

AN - SCOPUS:84876243023

SN - 1932-6203

VL - 8

JO - PLoS ONE

JF - PLoS ONE

IS - 4

M1 - e61177

ER -

Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this